Global Perspectives on Paediatric Uveitis: Bridging the Divide in Child-Centered Ocular Care. Ocular Immunology and Inflammation. 2025; 33(10):2241-2244.
Validation of the Pediatric Arthritis Ultrasound Scoring System for the Elbow, Wrist, and Finger Joints in Children with Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2025.
Long-term safety of canakinumab in patients with systemic juvenile idiopathic arthritis: 5-year results from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry. Pediatric Rheumatology. 2025; 23(1):105.
Monitoring of Juvenile Idiopathic Arthritis-Associated Uveitis in Long-Term Disease Remission: Consensus-Based Recommendations From the Multinational Interdisciplinary Working Group for Uveitis in Childhood. Arthritis Care and Research. 2025; 77(9):1106-1111.
Disease activity trajectories in paediatric lupus and associations with socioeconomic factors and patient-reported pain. Lupus Science and Medicine. 2025; 12(2).
Physician's global assessment of disease activity in juvenile idiopathic arthritis: consensus-based recommendations from an international task force. Annals of the Rheumatic Diseases. 2025; 84(8):1425-1436.
116 Clinical characteristics and quality of life measures in children with glaucoma suspect or glaucoma diagnoses in chronic, non-infectious uveitis. Journal of AAPOS. 2025; 29(4):104398.
Disease activity at two consecutive registry visits and subsequent medication escalation for patients with juvenile idiopathic arthritis in the CARRA registry. Pediatric Rheumatology. 2025; 23(1):77.
Genetic Inflammatory Diseases with Ocular Involvement. In: Genetic Diseases of the Eye. Oxford University Press (OUP); 2025:1070-1091.
POS0295 RELATIONSHIP AMONG A PEDIATRIC-SPECIFIC ULTRASOUND SCORING SYSTEM FOR THE EVALUATION OF ARTHRITIS AND BIOLOGIC MARKERS OF INFLAMMATION. Annals of the Rheumatic Diseases. 2025; 84:556.
Candidate Tear-Based Uveitis Biomarkers in Children with JIA Based on Arthritis Activity and Topical Corticosteroid Use. Ocular Immunology and Inflammation. 2025; 33(4):603-612.
25 Years of Biologics for the Treatment of Pediatric Rheumatic Disease: Advances in Prognosis and Ongoing Challenges. Arthritis Care and Research. 2025; 77(5):573-583.
A practical approach to uveitis screening in children with juvenile idiopathic arthritis. British Journal of Ophthalmology. 2025; 109(3):372-376.
Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial. The Lancet. 2025; 405(10475):303-313.
Racial Disparities and Achievement of the Low Lupus Disease Activity State: A CARRA Registry Study. Arthritis Care and Research. 2025; 77(1):38-49.
Achieving Medication-Free Remission in Patients With Juvenile Dermatomyositis. ACR Open Rheumatology. 2025; 7(1):e11751.
Effect of an Electronic Pill Bottle on Hydroxychloroquine Adherence in Pediatric Lupus: Results of a Novel Direct-to-Family Pilot Trial. ACR Open Rheumatology. 2025; 7(1):e11780.
Clinical outcomes in paediatric tubulointerstitial nephritis and uveitis syndrome (TINU). Eye. 2024; 38(17):3318-3324.
Treatment and Visual Outcomes in Pediatric Patients with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy: A Cohort Study. Ocular Immunology and Inflammation. 2024; 32(10):2441-2448.
Ultrawidefield Fluorescein Angiography and OCT Findings in Children and Young Adults with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy. Ophthalmology Retina. 2024; 8(11):1107-1112.
Interleukin (IL)-1/IL-6-Inhibitor-Associated Drug Reaction With Eosinophilia and Systemic Symptoms (DReSS) in Systemic Inflammatory Illnesses. Journal of Allergy and Clinical Immunology: In Practice. 2024; 12(11):2996-3013.e7.
Implementation study of the CARRA Uveitis Consensus Treatment Plans: feasibility for clinical practice and applicability for research. Pediatric Rheumatology. 2024; 22(1):88.
Comparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non-Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular-Course Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2024; 76(8):1090-1098.
New and Updated Recommendations for the Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis and Idiopathic Chronic Anterior Uveitis. Arthritis Care and Research. 2023; 75(5):975-982.
Screening, Monitoring, and Treating Children With Juvenile Idiopathic Arthritis-associated Uveitis: Visualizing Better Outcomes. Journal of Rheumatology. 2023; 50(3):300-303.
Therapeutic potential of JAK inhibitors in juvenile idiopathic arthritis-associated uveitis. Expert Review of Clinical Immunology. 2023; 19(7):689-692.
Alternative Biologic Therapy in Children Failing Conventional TNFα Inhibitors for Refractory, Noninfectious, Chronic Anterior Uveitis. American Journal of Ophthalmology. 2022; 244:183-195.
Relapse and Remission in Children With Chronic Noninfectious Uveitis Treated With Methotrexate. Journal of Rheumatology. 2022; 49(11):1289-1291.
Comprehensive Assessment of Quality of Life, Functioning, and Mental Health in Children With Juvenile Idiopathic Arthritis and Noninfectious Uveitis. Arthritis Care and Research. 2022; 74(8):1311-1320.
AAPOS Pediatric Uveitis Committee: Pediatric uveitis cases—a multidisciplinary approach to management challenges. Journal of AAPOS. 2022; 26(4):e68.
Ophthalmic sequelae and psychosocial impact in pediatric ebola survivors. EClinicalMedicine. 2022; 49:101483.
2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2022; 74(4):521-537.
2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. Arthritis & Rheumatology. 2022; 74(4):570-585.
2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis & Rheumatology. 2022; 74(4):553-569.
2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. Arthritis Care and Research. 2022; 74(4):505-520.
Assessing the Validity and Reliability of the Effects of Youngsters' Eyesight on Quality of Life Questionnaire Among Children With Uveitis. Arthritis Care and Research. 2022; 74(3):355-363.
International Consensus for the Dosing of Corticosteroids in Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis. Arthritis & Rheumatology. 2022; 74(2):263-273.
Uveitis in Children and Adolescents. Rheumatic Disease Clinics of North America. 2021; 47(4):619-641.
Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. The Lancet Rheumatology. 2021; 3(10):e707-e714.
Update on biologic therapies for juvenile idiopathic arthritis-associated uveitis. Annals of Eye Science. 2021; 6.
Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis. RMD Open. 2021; 7(1).
S100 proteins, cytokines, and chemokines as tear biomarkers in children with juvenile idiopathic arthritis-associated uveitis. Ocular Immunology and Inflammation. 2021; 29(7-8):1616-1620.
Ophthalmology perspectives on the management of juvenile idiopathic arthritis-associated uveitis: Eyeing the need for global, multidisciplinary collaborations. Clinical and Experimental Ophthalmology. 2021; 49(1):12-14.